

transformants, the 40–70 kb plasmid was detected, occasionally together with a 250 kb plasmid, which might result from the fusion of plasmids of smaller sizes. Southern hybridization using *bla*_{CTX-M}, *IncF* and *IncR* sequences as probes demonstrated that the 40–70 kb plasmid was of the *IncR* type and carried the *bla*_{CTX-M-15} gene.

Amongst the 24 *K. pneumoniae* isolates, 17/24 were from pets that underwent cystostomy or perineal urethrostomy in the same referral hospital, two surgical procedures that aim at solving bladder or urethral occlusions due to abundant crystals in urine in healthy animals. Of the seven others, three (strains 24492, 24418 and 24419; Table 1) were from animals visiting two neighbouring regular veterinary clinics. Interestingly, two of them (24492 and 24418) were from animals hospitalized for similar urinary tract surgery in the above-mentioned referral hospital a few weeks before, and one of these two dogs died after a severe chronic infectious cystitis, a classical post-operative complication of urethrostomy. The third isolate (24419) was recovered 2 months later in the same regular clinic as isolate 24418, but from a diabetic dog that had no history with the referral hospital. No epidemiological data could be obtained for the four remaining *K. pneumoniae* isolates, which were recovered from different veterinary clinics located in the same geographical area.

This study reports recurrent veterinary hospital-acquired infections in pets with a ciprofloxacin-resistant CTX-M-15-producing *K. pneumoniae* ST15 clone and this mirrors the situation observed for nosocomial infections in human hospitals. A spread of this clone outside the veterinary hospital through post-operative follow-up is also suggested. Of concern, this clone has been reported in humans and the hypothesis of a direct human origin, such as from a pets' owner, remains open. However, since the ST131/CTX-M-15 *E. coli* clone has also been reported in pets,⁵ a transfer to *K. pneumoniae* of the *bla*_{CTX-M-15} gene from *IncFII*-type plasmids found in *E. coli* is also plausible. Finally, this study is also the first report of a *bla*_{CTX-M-15} gene on an *IncR*-type plasmid in animals, a combination only recently reported in humans.^{3,8}

Acknowledgements

We are grateful to Alessandra Carattoli for providing the plasmid incompatibility group controls, and we thank Estelle Saras for her excellent assistance in this work. We also thank Claudine Tiberge for her skilled assistance, as well as the veterinary practitioners for their help in gathering all epidemiological data.

Funding

This work was supported by the Agence Nationale de Sécurité Sanitaire de l'Alimentation, de l'Environnement et du Travail (Anses).

Transparency declarations

None to declare.

References

1 Naseer U, Sundsfjord A. The CTX-M conundrum: dissemination of plasmids and *Escherichia coli* clones. *Microb Drug Resist* 2011; **17**: 83–97.

2 Lee MY, Ko KS, Kang CI et al. High prevalence of CTX-M-15-producing *Klebsiella pneumoniae* isolates in Asian countries: diverse clones and clonal dissemination. *Int J Antimicrob Agents* 2011; **38**: 160–3.

3 Coelho A, González-López JJ, Miró E et al. Characterisation of the CTX-M-15-encoding gene in *Klebsiella pneumoniae* strains from the Barcelona metropolitan area: plasmid diversity and chromosomal integration. *Int J Antimicrob Agents* 2010; **36**: 73–8.

4 Abbassi MS, Torres C, Achour W et al. Genetic characterisation of CTX-M-15-producing *Klebsiella pneumoniae* and *Escherichia coli* strains isolated from stem cell transplant patients in Tunisia. *Int J Antimicrob Agents* 2008; **32**: 308–14.

5 Platell JL, Johnson JR, Cobbold RN et al. Multidrug-resistant extraintestinal pathogenic *Escherichia coli* of sequence type ST131 in animals and foods. *Vet Microbiol* 2011; **153**: 99–108.

6 Ruiz E, Rojo-Bezares B, Saenz Y et al. Outbreak caused by a multi-resistant *Klebsiella pneumoniae* strain of new sequence type ST341 carrying new genetic environments of *aac(6')-Ib-cr* and *qnrS1* genes in a neonatal intensive care unit in Spain. *Int J Med Microbiol* 2010; **300**: 464–9.

7 Carattoli A, Bertini A, Villa L et al. Identification of plasmids by PCR-based replicon typing. *J Microbiol Methods* 2005; **63**: 219–28.

8 Ruiz E, Rezusta A, Saenz Y et al. New genetic environments of *aac(6')-Ib-cr* gene in a multiresistant *Klebsiella oxytoca* strain causing an outbreak in a pediatric intensive care unit. *Diagn Microbiol Infect Dis* 2011; **69**: 236–8.

J Antimicrob Chemother 2012

doi:10.1093/jac/dkr543

Advance Access publication 3 January 2012

Role of MexAB-OprM in intrinsic resistance of *Pseudomonas aeruginosa* to temocillin and impact on the susceptibility of strains isolated from patients suffering from cystic fibrosis

Julien M. Buyck¹, Sophie Guénard², Patrick Plésiat², Paul M. Tulkens¹ and Françoise Van Bambeke^{1*}

¹Cellular and Molecular Pharmacology, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium; ²Laboratoire de Bactériologie, Hôpital Jean Minjoz, Besançon, France

*Corresponding author. Tel: +32-2-7647378; Fax: +32-2-7647373; E-mail: francoise.vanbambeke@uclouvain.be

Keywords: ticarcillin, MexXY-OprM, MexCD-OprJ, MexEF-OprN, Phe-Arg-β-naphthylamide

Sir,
Temocillin (6-α-methoxy-ticarcillin) is resistant to most β-lactamases, including AmpC and extended-spectrum β-lactamases, and is therefore considered a useful alternative to carbapenems in infections caused by several resistant Gram-negative pathogens.¹ Yet, temocillin is inactive against

Table 1. MICs of temocillin and ticarcillin for *P. aeruginosa* strains with known efflux characteristics, as measured in Mueller–Hinton broth (MHB) or in MHB supplemented with the broad-spectrum efflux inhibitor PAβN (50 mg/L)

Strain	Origin or ref.	Description	Efflux characteristics, gene expression level					MIC (mg/L)	
			<i>mexA</i> ^a	<i>mexX</i> ^a	<i>oprM</i> ^a	<i>mexC</i> ^b	<i>mexE</i> ^b	temocillin (+PAβN ^c)	ticarcillin (+PAβN ^c)
Reference strain									
PAO1	ATCC		1	1	1	—	—	256–512 (64)	32 (16)
Engineered strains									
FB1	d	PAO1 <i>mexB::FRT</i>	ND	ND	ND	ND	ND	2	0.5
CB536	e	PAO1 Δ <i>mexCD-oprJ</i>	1.09	1.65	ND	—	+	128 (16)	8 (1)
CB603	e	PAO1 Δ <i>mexEF-oprN</i>	1.21	1.02	0.51	—	—	128 (32)	16 (16)
CB602	e	PAO1 <i>mexXY::FRT</i>	1.10	0.06	0.55	—	+	64 (16)	16 (16)
PAO1 <i>mexAB</i>	f	PAO1 <i>mexAB::FRT</i>	0 ^g	1.08	ND	—	+	4 (2)	2 (2)
PAO200	f	PAO1 Δ <i>mexAB-oprM</i>	0 ^g	1.26	ND	—	—	4 (0.5)	2 (0.5)
SG01	h	PAO1 Δ <i>oprM</i>	ND	ND	ND	ND	ND	2	0.5
CMZ091	i	PAO1 Δ <i>mexZ</i> (MeXY overproducer)	ND	ND	ND	ND	ND	256	16
CM114	h	PAO1 Δ <i>mexXY</i>	ND	ND	ND	ND	ND	256	32
4098	j	PAO1 <i>met-9020 pro-9024 blaP-9208</i> (weak AmpC producer)	1.26	1.62	0.33	—	—	128	8
4098E	k	4098 overproducing MexAB-OprM	5.41	1.31	3.19	—	—	1024 (512)	64 (32)
4098ET	k	4098E Δ <i>oprM</i>	2.18	0.04	0.02	—	—	2 (1)	2 (1)
PA Δ <i>dacB</i>	m	PAO1 Δ <i>dacB::lox</i> (AmpC overproducer)	ND	ND	ND	ND	ND	128	64
Clinical isolates from patients with HAP									
168B	n		1.15	0.89	ND	—	—	256 (32)	16 (16)
156	n		0.33	0.95	ND	—	+	512 (64)	256 (32)
68	n		0.87	44.94	ND	—	—	512 (64)	32 (16)
34	n		6.86	1.26	ND	—	—	>1024 (512)	256 (128)
333A	n		2.17	2.29	ND	—	—	>1024 (1024)	128 (128)
11	n		3.56	5.68	ND	—	—	1024 (64)	32 (32)
12	n		3.97	9.04	ND	+	+	512 (128)	64 (64)

			Efflux characteristics, alterations					
			<i>mexA</i>	MexA	<i>mexB</i>	MexB		
Clinical isolates from cystic fibrosis patients								
3020S	^d		—	—	—	—	128	16
3020R	^d	isogenic to 3020S with deletion in <i>mexA</i>	Δ 112 nt (370–482)	aberrant	—	—	2	1
3525			—	—	—	—	512	32
3807		isogenic to 3525 with mutation in <i>mexA</i>	G214A	G72S	—	—	32	4
2715	^d	mutation in <i>mexA</i>	A590G	Y197C	—	—	32	2
616		mutation in <i>mexA</i>	C752T	S251F	—	—	1	0.5
2729	^d	deletion in <i>mexA</i>	Δ 8 nt (576–583)	aberrant	—	—	2	1
2933	^d	deletion in <i>mexA</i>	Δ 1 nt (870)	aberrant	—	—	2	0.5
2998	^d	deletion in <i>mexA</i>	C205T	truncated	—	—	2	0.25
2721	^d	deletion in <i>mexA</i>	Δ 1 nt (860)	aberrant	—	—	1	0.25
2716	^d	mutation in <i>mexB</i>	—	—	A776T	Q259L	1	0.5
2804	^d	deletion in <i>mexB</i>	—	—	Δ 1 nt (2147)	aberrant	4	1
2858	^d	deletion in <i>mexB</i>	—	—	Δ 1 nt (494)	aberrant	1	0.5
3066		deletion in <i>mexB</i>	—	—	G2364A	truncated	1	0.5

ND, not determined.

^aReal-time quantitative PCR [threshold ratio compared with PAO1; values shown in bold are considered as denoting highly significant overexpression (≥ 2 and ≥ 5 for *mexA* and *mexX*, respectively, based on the recommendations of the manufacturer of the kit used for their detection; no threshold value set for *oprM*); values interpreted as denoting an absence (or quasi-absence) of detection are shown in italics].

^bRT-PCR [semi-quantitative detection (+/–)].

^cPA β N (broad-spectrum efflux inhibitor) used at 50 mg/L.

^dVettoretti *et al. Antimicrob Agents Chemother* 2009; **53**: 1987–97.

^eRobertson *et al. J Bacteriol* 2007; **189**: 6870–81.

^fMima *et al. J Bacteriol* 2007; **189**: 7600–9.

^gComplete absence of detection.

^hS. Guénard and P. Plésiat (unpublished results).

ⁱMuller *et al. Antimicrob Agents Chemother* 2011; **55**: 1211–21.

^jLi *et al. Antimicrob Agents Chemother* 1994; **38**: 1732–41.

^kHamzehpour *et al. Antimicrob Agents Chemother* 1995; **39**: 2392–6.

^lNo growth in the presence of PA β N (PA β N MIC=25 mg/L for this strain).

^mMoya *et al. PLoS Pathog* 2009; **5**: e1000353.

ⁿIsolated from ICUs in Belgium.

Pseudomonas aeruginosa, possibly because of poor permeation across the outer membrane barrier and/or reduced binding to penicillin-binding proteins.¹ However, the role of multidrug efflux systems has not been examined so far. Three multidrug efflux systems have been reported to export β -lactams in *P. aeruginosa*, namely (from least to most effective) MexXY-OprM, MexCD-OprJ and MexAB-OprM.² We wondered whether temocillin could be the substrate of one or several of these transporters.

Temocillin (Eumedica, Brussels, Belgium) and ticarcillin (disodium salt; Sigma-Aldrich, St Louis, MO, USA) were tested against: (i) the wild-type reference strain PAO1; (ii) a panel of laboratory strains with specific disruption(s) of the gene(s) encoding the three transporters mentioned above and MexEF-OprN, another efflux pump accommodating fluoroquinolones, trimethoprim and chloramphenicol, but not β -lactams,² and producing different levels of AmpC; (iii) clinical isolates from patients hospitalized in intensive care units (ICUs) with hospital-acquired pneumonia (HAP); and (iv) strains from cystic fibrosis patients that were found to be hypersusceptible to carbenicillin and ticarcillin (Tic^{HS} phenotype) due to mutations in *mexA* or *mexB*.³ MICs were determined by microdilution in Mueller-Hinton broth (pH 7.4, 24 h) without or with the broad-spectrum efflux inhibitor Phe-Arg- β -naphthylamide (PA β N; 50 mg/L; Sigma-Aldrich).⁴ The expression of *mexA* and *mexX* was measured by quantitative real-time PCR, and that of *mexC* and *mexE* was measured by semi-quantitative RT-PCR. *mexA*, *mexB* and *oprM* were sequenced in strains from cystic fibrosis patients.³

The MIC of temocillin for PAO1 was ≥ 256 mg/L, but fell to 64 mg/L when tested in the presence of PA β N, a broad-spectrum competitive inhibitor of efflux transporters (Table 1), suggesting a role of active efflux in the intrinsic high-level resistance of *P. aeruginosa* to temocillin. The magnitude of the inhibitory effect of PA β N, however, varies depending on the substrate.⁴ To better quantify the impact of efflux on temocillin MICs, and also to identify the transporter(s) responsible for its efflux, we used isogenic strains deficient in the main efflux systems. Disruption of MexCD-OprJ, MexEF-OprN or MexXY only slightly affected the temocillin MIC (2–3 log₂ reduction), consistent with the strongly repressed expression of these three systems in wild-type strains. In contrast, disruption of *mexB*, *mexAB*, *oprM* or *mexAB-oprM* decreased MICs to values as low as 2–4 mg/L, with a minimal additional effect of PA β N. Conversely, overexpression of *mexAB*, but not of *mexXY*, further increased the temocillin MIC compared with PAO1. This clearly indicates that MexAB-OprM-driven efflux strongly contributes to the intrinsic resistance of *P. aeruginosa* to temocillin, while the other Mex systems only play a minor role. We also confirmed the stability of temocillin to AmpC.

To examine the clinical relevance of our observations, we measured temocillin MICs for isolates collected from ICU patients with HAP. All values were high, but those from isolates overexpressing *mexA* were higher than those for PAO1, corroborating the importance of this efflux system in temocillin resistance. In parallel, we found that isolates obtained from cystic fibrosis patients and showing hypersusceptibility to ticarcillin were also hypersusceptible to temocillin, with MICs ranging between 1 and 4 mg/L in most cases. Interestingly enough, however, the MICs for some isolates with single nucleotide mutations in *MexA* (G72S and Y197C) remained moderately elevated (32 mg/L), suggesting that these mutated proteins remained partly functional.

Noteworthy, when considering all isolates examined here, differences between temocillin and ticarcillin MICs were much greater in isolates producing a functional or partially functional MexAB-OprM pump than in deficient strains (with temocillin MICs being 3–5 log₂ dilutions higher than those of ticarcillin). This suggests that temocillin is a preferential substrate for the MexAB-OprM transporter compared with ticarcillin, pointing to a potential role of the 6- α -methoxy substituent in its recognition and efflux.

While intrinsic resistance of *P. aeruginosa* to temocillin makes this antibiotic unusable in most conventional clinical set-ups, we see here that impairment of efflux lowers the MICs to values below the current clinical susceptibility breakpoint for Enterobacteriaceae (16 mg/L; UK and Belgium) or even the pharmacokinetic/pharmacodynamic breakpoint proposed for a 4 g daily dose (8 mg/L).⁵ This may further trigger current efforts in designing clinically useful inhibitors of the MexAB-OprM transporter, since such combined therapy could provide the clinician with a useful alternative to current antipseudomonal β -lactams, especially if considering temocillin's remarkable β -lactamase stability. The present data may also have potential immediate application for cystic fibrosis patients. These patients can be infected by *Burkholderia cepacia*, against which temocillin is active and, therefore, commonly used.¹ Because of the large prevalence of *P. aeruginosa* isolates with the hypersusceptible Tic^{HS} phenotype in this patient population,³ temocillin could contribute to their eradication as well. Testing for temocillin susceptibility of *P. aeruginosa* isolated from cystic fibrosis patients appears, therefore, potentially useful.

Acknowledgements

We thank the clinical microbiology laboratories from our collaborating hospitals for collecting clinical isolates from patients suffering from HAP (see list in Riou *et al. Int J Antimicrob Agents* 2010; **36**: 513–22) and Eumedica, Brussels, Belgium, for providing us with microbiological standards of temocillin. We are also grateful to Virginie Mohymont for excellent technical assistance.

Funding

This work was supported by the Belgian *Fonds pour la Recherche Scientifique Médicale* (FRSM; grants 3.4597.06 and 3.4583.08). F. V. B. is *Maître de Recherches* of the Belgian *Fonds de la Recherche Scientifique* (F.R.S.-FNRS). J. M. B. is supported by the BioWin programme of the Belgian *Région Wallonne* (DG06).

Transparency declarations

P. M. T. is an unpaid adviser of Eumedica (manufacturer of temocillin); he does not have any financial interests in this company. J. M. B., S. G., P. P. and F. V. B. have no conflicts of interest to declare.

References

- Livermore DM, Tulkens PM. Temocillin revived. *J Antimicrob Chemother* 2009; **63**: 243–5.
- Van Bambeke F, Glupczynski Y, Plesiat P *et al.* Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the

future of antimicrobial therapy. *J Antimicrob Chemother* 2003; **51**: 1055–65.

3 Vettoretti L, Plesiat P, Muller C *et al.* Efflux unbalance in *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. *Antimicrob Agents Chemother* 2009; **53**: 1987–97.

4 Lomovskaya O, Warren MS, Lee A *et al.* Identification and characterization of inhibitors of multidrug resistance efflux pumps in *Pseudomonas aeruginosa*: novel agents for combination therapy. *Antimicrob Agents Chemother* 2001; **45**: 105–16.

5 De Jongh R, Hens R, Basma V *et al.* Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. *J Antimicrob Chemother* 2008; **61**: 382–8.

J Antimicrob Chemother 2012

doi:10.1093/jac/dkr514

Advance Access publication 6 December 2011

Report of a *Salmonella enterica* serovar Typhi isolate from India producing CMY-2 AmpC β-lactamase

Karthikeyan Kumarasamy* and Padma Krishnan

Department of Microbiology, Dr. ALM PG IBMS, University of Madras, Taramani, Chennai 600 113, India

*Corresponding author. Tel: +91-99947-51555; Fax: +91-44245-40709; E-mail: skk.microbes@gmail.com

Keywords: bloodstream infections, ceftriaxone resistance, ISEcp1, IncA/C-type plasmids

Sir,

The emergence of multidrug-resistant *Salmonella* infection is an ever-increasing problem and is a cause for serious global concern. Resistance to third-generation cephalosporins in *Salmonella* has been attributed to the production of extended-spectrum β-lactamases (ESBLs), but resistance mediated by AmpC and KPC or metallo-β-lactamases ('MBLs') has also been reported.¹ In particular, the AmpC β-lactamases reported in

non-typhoidal *Salmonella* (NTS) are derivatives of CMY, DHA-1 and ACC-1,¹ although ACC-1-producing *Salmonella* Typhi has been recently identified in India.²

A *Salmonella enterica* serovar Typhi (designated B729) isolate was isolated from the blood culture of a child admitted to a hospital in Salem, Tamil Nadu, in December 2009. Species identification and antibiotic susceptibility were performed using an automated system (VITEK-2, bioMérieux Inc.). The isolate was further confirmed by serotyping using specific antiserum. This isolate was resistant to all the β-lactams (except carbapenems), but susceptible to non-β-lactam antibiotics. MICs of various antibiotics were determined using the agar dilution method, and susceptibility data were interpreted using EUCAST breakpoints (version 1.3; January 2011), while tetracycline and nalidixic acid susceptibilities were interpreted as recommended by CLSI guidelines (January 2011), as EUCAST breakpoints are not defined. B729 showed elevated MICs of all the β-lactams except carbapenems (<0.25 mg/L), co-trimoxazole (<1 mg/L), chloramphenicol (4 mg/L), aminoglycosides (<0.5 mg/L), tetracycline (2 mg/L), nalidixic acid (2 mg/L) and ciprofloxacin (<0.015 mg/L).

The presence of AmpC was determined by phenotypic methods, namely an AmpC disc test and a modified three-dimensional test.² PCR assays for the genes encoding β-lactamases³ showed that B729 carried *bla*_{CMY-2}. In addition, PCR mapping experiments⁴ and sequencing analysis revealed that the *bla*_{CMY-2} was flanked by *ISEcp1* and a *blc* gene, similar to the NTS isolates previously reported in the USA, Taiwan and Europe.

Plasmid analysis using the Kieser technique revealed that B729 harboured three plasmids, with respective sizes of 90, 70 and 25 kb, using *Escherichia coli* NCTC 50192 as a reference marker. To determine whether the AmpC phenotype was transferable, transconjugation experiments were attempted using a ciprofloxacin-resistant clinical isolate of *Salmonella* Typhimurium and the azide-resistant *E. coli* J53 as the recipient. Transconjugants were selected on MacConkey agar plates containing cefotaxime (2 mg/L) and ciprofloxacin (1 mg/L) or sodium azide (200 mg/L). The AmpC phenotype was successfully transferred to both of the species tested. The plasmids of the transconjugants showing an AmpC phenotype were typed by PCR-based replicon typing.⁵ The plasmid profile revealed that the *E. coli* J53-p729A transconjugant carried a *bla*_{CMY-2}-positive 70 kb plasmid that belonged to the IncA/C incompatibility type (Table 1).

Table 1. Characteristics of *Salmonella* Typhi B729, transconjugants, *E. coli* J53 and *Salmonella* Typhimurium (clinical strain)

Strain	<i>bla</i> gene	Plasmid			MIC (mg/L)						
		<i>rep</i> typing	size (kb)	FT	AMP	AMC	CRO	CTX/CLA	CAZ	FOX	TZP
<i>Salmonella</i> Typhi B729	<i>bla</i> _{CMY-2}	—	90, 70, 24	—	>256	>128	>256	>128	>256	>128	128
<i>E. coli</i> -p729A	<i>bla</i> _{CMY-2}	IncA/C	70	2.3×10 ⁻²	>256	>128	>256	>128	>256	>128	32
<i>Salmonella</i> Typhimurium-p729A	<i>bla</i> _{CMY-2}	IncA/C	70	5.4×10 ⁻⁴	>256	>128	>256	>128	>256	>128	32
<i>E. coli</i> J53	—	—	—	—	<2	<2	<0.5	<0.5	<0.5	8	<4
<i>Salmonella</i> Typhimurium	—	—	—	—	<2	<2	<0.5	<0.5	<0.5	8	<4

AMP, ampicillin; AMC, amoxicillin/clavulanic acid; CRO, ceftriaxone; CTX/CLA, cefotaxime/clavulanic acid; CAZ, ceftazidime; FOX, cefoxitin; TZP, piperacillin/tazobactam; FT, frequency of transfer or transconjugation efficiency.